Brought to you by 
Bayer and Schering-Plough in marketing alliance
20 Jul 2005
Executive Summary
As part of its corporate restructuring, Bayer AG has licensed Schering-Plough exclusive US and Puerto Rican marketing and distribution rights to all the primary care pharma products of its US subsidiary Bayer HealthCare. In turn, S-P has licensed Bayer Japanese co-promotion rights to its cholesterol absorption inhibitor Zetia (ezetimibe), which is currently under review for CV disorders (if approved, Bayer Yakuhin will market it).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
- Product or Technology Swap
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com